Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Applies For EU Approval Of COVID-19 Vaccine

UK’s Controversial Dosing Schedule For Pfizer/BioNTech Jab May Face Legal Scrutiny

Executive Summary

The European Medicines Agency may issue an opinion on approving AstraZeneca’s COVID-19 vaccine by 29 January if the data are robust and complete and any additional data requests are dealt with promptly.

You may also be interested in...



Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir

The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.

EU Parliamentarians To Get Sight Of First COVID-19 Vaccine Contract

The advance purchase agreement signed by CureVac and the European Commission for the supply of a coronavirus vaccine is being made available for scrutiny, but only by MEPs and in the confines of the European Parliament.

EU Approval Of Oxford/AstraZeneca COVID-19 Vaccine Expected By End Of January

AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel